Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.

You may also be interested in...



Deal Watch: Anticipated Shire/Baxalta Merger Steals Attention From J.P. Morgan

Industry's leading deal-making stage shows continued focus on immuno-oncology, with activity by Merck, Novartis and AstraZeneca.

Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play

A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.

Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS

Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel